CoChat

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Open access
Bringhen, Sara, Petrucci, Maria Teresa, Larocca, Alessandra, Conticello, Concetta, Rossi, Davide, Magarotto, Valeria, Musto, Pellegrino, Boccadifuoco, Luana, Offidani, Massimo, Omedé, Paola, Gentilini, Fabiana, Ciccone, Giovannino, Benevolo, Giulia, Genuardi, Mariella, Montefusco, Vittorio, Oliva, Stefania, Caravita, Tommaso, Tacchetti, Paola, Boccadoro, Mario, Sonneveld, Pieter, Palumbo, Antonio · 2014 · Blood
Cited by 153

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Key Points: This is the first study of carfilzomib-cyclophosphamide-dexamethasone in elderly patients with newly diagnosed multiple myeloma. Carfilzomib-cyclophosphamide-dexamethasone induced high complete response rates and was associated with low toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2014-03-563759

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 20

  1. Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012., Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 · DOI · Paper page
  2. Palumbo, 2011, Multiple myeloma., N Engl J Med, 364, 1046, 10.1056/NEJMra1011442 · DOI · Paper page
  3. Kumar, 2012, Continued improvement in survival in multiple myeloma and the impact of novel agents [abstract]., Blood, 120, 3972, 10.1182/blood.V120.21.3972.3972 · doi:10.1182/blood.v120.21.3972.3972
  4. Fayers, 2011, Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials., Blood, 118, 1239, 10.1182/blood-2011-03-341669 · DOI · Paper page
  5. Richardson, 2006, Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib., J Clin Oncol, 24, 3113, 10.1200/JCO.2005.04.7779 · DOI · Paper page
  6. Palumbo, 2013, Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials., Haematologica, 98, 87, 10.3324/haematol.2012.067058 · DOI
  7. Morgan, 2011, Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation., Blood, 118, 1231, 10.1182/blood-2011-02-338665 · DOI · Paper page
  8. Mohty, 2010, Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations., Haematologica, 95, 311, 10.3324/haematol.2009.012674 · DOI · Paper page
  9. Siegel, 2012, A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma., Blood, 120, 2817, 10.1182/blood-2012-05-425934 · DOI · Paper page
  10. Bryant, 1995, Incorporating toxicity considerations into the design of two-stage phase II clinical trials., Biometrics, 51, 1372, 10.2307/2533268 · DOI · Paper page
  11. Kropff, 2009, DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma., Ann Hematol, 88, 1125, 10.1007/s00277-009-0726-6 · DOI
  12. Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma., N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI · Paper page
  13. Gay, 2011, Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients., Blood, 117, 3025, 10.1182/blood-2010-09-307645 · DOI · Paper page
  14. Ludwig, 2012, IMWG consensus on maintenance therapy in multiple myeloma., Blood, 119, 3003, 10.1182/blood-2011-11-374249 · DOI · Paper page
  15. Bringhen, 2013, Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials., Haematologica, 98, 980, 10.3324/haematol.2012.075051 · DOI · Paper page
  16. Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial., Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4 · DOI · Paper page
  17. Moreau, 2013, Carfilzomib plus melphalan and prednisone (CMP) is a promising combination therapy for the treatment of elderly patients with newly diagnosed multiple myeloma: results of a phase I/II trial in 68 cases [abstract]., Blood, 122, 1933, 10.1182/blood.V122.21.1933.1933 · doi:10.1182/blood.v122.21.1933.1933
  18. Jasielec, 2013, Predictors of treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in newly diagnosed multiple myeloma (NDMM) [abstract]., Blood, 122, 3220, 10.1182/blood.V122.21.3220.3220 · DOI
  19. Jakubowiak, 2012, A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma., Blood, 120, 1801, 10.1182/blood-2012-04-422683 · DOI · Paper page
  20. Arastu-Kapur, 2011, Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events., Clin Cancer Res, 17, 2734, 10.1158/1078-0432.CCR-10-1950 · DOI · Paper page

Cited by

See all 153

Metadata

Authors
Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedé, P., Gentilini, F., Ciccone, G., Benevolo, G., Genuardi, M., Montefusco, V., Oliva, S., Caravita, T., Tacchetti, P., Boccadoro, M., Sonneveld, P., & Palumbo, A.
Venue
Blood
Published
2014-07-03
Volume
124
Issue
1
Pages
63-69
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2088674645
Cited by
153
References
6
FWCI
13.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. https://app.cochat.ai/papers/10.1182/blood-2014-03-563759
The paper
Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedé, P., Gentilini, F., Ciccone, G., Benevolo, G., Genuardi, M., Montefusco, V., Oliva, S., Caravita, T., Tacchetti, P., Boccadoro, M., . . . Palumbo, A. (2014). Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. https://doi.org/10.1182/blood-2014-03-563759

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.